Zhejiang Jingxin Pharmaceutical Co Ltd

Jingxin Pharmaceutical released its 2026 interim report. Total operating revenue was 1.987 billion yuan, down 1.46% from the same period last year. Net profit attributable to the parent company was 352 million yuan, down 9.35% year-on-year. Net cash inflow from operating activities was 477 million yuan. The asset-liability ratio was 24.07%, gross margin was 50.50%, and diluted earnings per share was 0.43 yuan, down 6.52% year-on-year. The number of shareholders was 32,900, and the top ten shareholders held 46.80% of the total share capital.

Jingxin Pharmaceutical released its 2026 interim report on August 26. During the reporting period, the company achieved operating revenue of 1.987 billion yuan, down 1.46 percent year on year. Net profit attributable to the parent company was 352 million yuan, down 9.35 percent year on year. Non-GAAP net profit was 342 million yuan, down 5.15 percent year on year. The company relied on coordinated efforts across its three core segments: psychiatry and neurology, cardiovascular and cerebrovascular, and medical devices. Among them, medical device revenue reached 379 million yuan, up 7.01 percent year on year, becoming a growth highlight. Pharmaceutical manufacturing revenue was 1.609 billion yuan, down 3.26 percent year on year. Sales of the innovative drug Dimdazenil capsules reached 153 million yuan. Cariprazine hydrochloride capsules received the first generic approval in China. However, revenue from the active pharmaceutical ingredient business declined due to the market environment, and increased foreign exchange gains and losses weighed on net profit. Net operating cash flow was 477 million yuan, up 21.38 percent year on year, showing that the main business's cash generation capability has strengthened.

Jingxin Pharmaceutical released its 2026 half-year report. Net profit attributable to the parent for the first half was 352 million yuan, down 9.3% year-on-year. Operating revenue was 1.99 billion yuan, down 1.5% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 342 million yuan, down 5.1% year-on-year. Net operating cash flow was 477 million yuan, up 21.4% year-on-year. Earnings per share were 0.4084 yuan. In the second quarter, operating revenue was 1.06 billion yuan, up 0.3% year-on-year. Net profit attributable to the parent was 186 million yuan, down 17.0% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 186 million yuan, down 12.7% year-on-year. As of the end of the second quarter, total assets were 7.953 billion yuan, down 2.1% from the end of the previous year. Net assets attributable to the parent were 6.0 billion yuan, up 2.9% from the end of the previous year. The company said that during the reporting period, the profitability of its main business grew steadily and its product structure continued to improve, with a focus on innovative drug research and development in the psychiatric, neurological, and cardiovascular and cerebrovascular fields. During the reporting period, sales of Dimdazenil capsules reached 153 million yuan, and the share of revenue from innovative drugs steadily increased. Cariprazine hydrochloride capsules received a drug registration certificate in June 2026, becoming the first generic version in China.